Pembrolizumab: a potential game-changer in the treatment of advanced hepatocellular carcinoma

Dmitrii Shek; Golo Ahlenstiel

doi:10.21037/cco-23-44

Pembrolizumab: a potential game-changer in the treatment of advanced hepatocellular carcinoma

Dmitrii Shek
, Golo Ahlenstiel

Westmead Millennium Institute for Medical Research
Blacktown Hospital

Research output: Contribution to journal › Article › peer-review

5 Downloads (Pure)

Abstract

Liver cancer is the 5th most common cancer in men and 9th among women. In 2020, almost 900,000 new cases were registered across the globe with 830,200 people died from this disease. Hepatocellular carcinoma (HCC) is a
primary malignant liver tumour with the higher incidence and mortality in Asia as compared to Western countries.

Original language	English
Article number	47
Number of pages	4
Journal	Chinese Clinical Oncology
Volume	12
Issue number	5
DOIs	https://doi.org/10.21037/cco-23-44
Publication status	Published - Oct 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

hepatocellular carcinoma (HCC)
Immune-checkpoint inhibitors (ICIs)
immune-related adverse events
liver cancer
T cells

Access to Document

10.21037/cco-23-44Licence: CC BY-NC-ND

Full textFinal published version, 317 KBLicence: CC BY-NC-ND

Cite this

@article{7198aaf1cbb344be92ad466354647e9c,

title = "Pembrolizumab: a potential game-changer in the treatment of advanced hepatocellular carcinoma",

abstract = "Liver cancer is the 5th most common cancer in men and 9th among women. In 2020, almost 900,000 new cases were registered across the globe with 830,200 people died from this disease. Hepatocellular carcinoma (HCC) is a primary malignant liver tumour with the higher incidence and mortality in Asia as compared to Western countries.",

keywords = "hepatocellular carcinoma (HCC), Immune-checkpoint inhibitors (ICIs), immune-related adverse events, liver cancer, T cells",

author = "Dmitrii Shek and Golo Ahlenstiel",

year = "2023",

month = oct,

doi = "10.21037/cco-23-44",

language = "English",

volume = "12",

journal = "Chinese Clinical Oncology",

issn = "2304-3865",

publisher = "AME Publishing Company",

number = "5",

}

TY - JOUR

T1 - Pembrolizumab

T2 - a potential game-changer in the treatment of advanced hepatocellular carcinoma

AU - Shek, Dmitrii

AU - Ahlenstiel, Golo

PY - 2023/10

Y1 - 2023/10

N2 - Liver cancer is the 5th most common cancer in men and 9th among women. In 2020, almost 900,000 new cases were registered across the globe with 830,200 people died from this disease. Hepatocellular carcinoma (HCC) is a primary malignant liver tumour with the higher incidence and mortality in Asia as compared to Western countries.

AB - Liver cancer is the 5th most common cancer in men and 9th among women. In 2020, almost 900,000 new cases were registered across the globe with 830,200 people died from this disease. Hepatocellular carcinoma (HCC) is a primary malignant liver tumour with the higher incidence and mortality in Asia as compared to Western countries.

KW - hepatocellular carcinoma (HCC)

KW - Immune-checkpoint inhibitors (ICIs)

KW - immune-related adverse events

KW - liver cancer

KW - T cells

UR - https://www.scopus.com/pages/publications/85177103317

U2 - 10.21037/cco-23-44

DO - 10.21037/cco-23-44

M3 - Article

C2 - 37691347

AN - SCOPUS:85177103317

SN - 2304-3865

VL - 12

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

IS - 5

M1 - 47

ER -

Pembrolizumab: a potential game-changer in the treatment of advanced hepatocellular carcinoma

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this